Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children’s Oncology Group

Analysis of 1,014 patients found that those given dexarazoxone with AML treatment had a lower risk for left ventricular systolic dysfunction than those given AML treatment alone (26.5% vs 42.2%, HR 0.55, 95% CI 0.36-0.86) without increasing non-cardiac toxicities.


Journal of Clinical Oncology